Akebia Therapeutics Stock News

Man Group plc reduced its stake in shares of Akebia Therapeutics Inc (NASDAQ:AKBA) by 6.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Excha

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today announced the appoin

Ladies and gentlemen, thank you for standing by and welcome to the Humana Fourth Quarter Earnings Call.

Victory Capital Management Inc. raised its position in Akebia Therapeutics Inc (NASDAQ:AKBA) by 50.9% in the 4th quarter, HoldingsChannel reports. The fund owned 30,111 shares of the biopharmaceutical

Advisor Group Inc. boosted its stake in Akebia Therapeutics Inc (NASDAQ:AKBA) by 52.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC).

Shares of Akebia Therapeutics Inc (NASDAQ:AKBA) have been given a consensus recommendation of “Buy” by the seven brokerages that are presently covering the company, MarketBeat.com reports. Two res

Credit Suisse AG cut its stake in Akebia Therapeutics Inc (NASDAQ:AKBA) by 17.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm

AQR Capital Management LLC grew its holdings in shares of Akebia Therapeutics Inc (NASDAQ:AKBA) by 231.4% in the 4th quarter, according to the company in its most recent filing with the Securities and

Amalgamated Bank lifted its position in shares of Akebia Therapeutics Inc (NASDAQ:AKBA) by 9.7% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, granted eight newly-hired

Investors need to pay close attention to Akebia Therapeutics (AKBA) stock based on the movements in the options market lately.

Investors need to pay close attention to Akebia Therapeutics (AKBA) stock based on the movements in the options market lately.

Akebia Therapeutics (NASDAQ:AKBA) was upgraded by ValuEngine from a “hold” rating to a “buy” rating in a research report issued on Thursday, ValuEngine reports. AKBA has been the topic of a nu